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Abstract
CaMKII!, a calcium/calmodulin-dependent protein kinase, plays pivotal roles in the development of heart disease.
In this issue of The Journal of Pathology, Salma Awad and colleagues demonstrate that CaMKII! is engaged in
both pathological hypertrophy and heart failure. By analysis of mouse and human heart samples, they found
that the level of CaMKII! is increased in both pathological processes. Further studies demonstrated that CaMKII!
mediates the phosphorylation of histone H3 at serine 10 (H3S10), which then tethers the chaperone protein
14-3-3 to promoter regions of fetal cardiac genes to activate their transcription. Combined with recent highlights
on transcription regulation, this study revealed a fuzzy boundary between pathological hypertrophy and subsequent
heart failure and indicates that current therapeutic strategies towards heart failure may have potential risks to
patients.
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Heart failure is a major public health concern in the mod-
ern world. After chronic or acute pathological changes,
the heart fails to pump sufficient blood for the circulatory
system, which results in massive cardiomyocyte death
due to lack of nutrition, oxygen, and waste removal.
Pathological hypertrophy, as a well-known compen-
satory response process, often induces the accumulation
of fetal cardiac proteins in cardiomyocytes and substan-
tial pathological changes of the heart, thereby leading
to chronic heart failure. Many studies have focused on
explaining the molecular bases of hypertrophy, rather
than heart failure itself. In this issue of the journal, Salma
Awad and colleagues reveal a novel connection between
histone modification and heart failure-related transcrip-
tional reprogramming [1].
It is well known that hypertrophic signals induce rapid
activation of immediate-early genes and increase the
expression of fetal cardiac genes. Awad et al revealed
that calcium/calmodulin-dependent protein kinase
II delta (CaMKIIδ) is required for these processes
[1,2]. According to their observations, CaMKIIδ levels
increase not only in hypertrophic cardiomyocytes, but
also in failing hearts from heart transplant patients.
The enriched CaMKIIδ can be tethered to the promoter
regions of fetal cardiac genes such as ANP, β-MHC,
c-MYC, and GATA4, and is thought to be responsible
for phosphorylation of the nucleosomal histone, H3, at
serine 10 (H3S10). Further investigation showed that
this phosphorylated H3S10 (H3S10ph) is able to bind
14-3-3 chaperone protein, thereby promoting the teth-
ering of specific transcription factors such as GATA4 or
MEF2 to allow proper elongation of fetal cardiac genes
by RNA polymerase II (RNAPII). In contrast, knockout
of CaMKIIδ abolished both the phosphorylation of
H3S10 and the reactivation of fetal genes in mouse
cardiomyocytes even under pathological stress, further
confirming the role of CaMKIIδ in regulating cardiac
hypertrophy and end-stage failure through phosphory-
lating H3S10 [1,2]. Therefore, their studies provide an
insight into the mechanism of cardiac hypertrophy and
heart failure at the molecular level.
Of note, the functions of CaMKIIδ in regulating car-
diac pathological processes are more complicated and
beyond those addressed by Awad et al. First, besides
phosphorylating H3S10, CaMKIIδ is also reported to
phosphorylate HDAC4, a member of class II histone
deacetylases (HDACs), and thereby drive it out of the
nucleus. This not only releases the HDAC4-bound
MEF2 for the expression of MEF2-mediated hyper-
trophic genes, but also enhances the acetylation of
nucleosomal histones for remodelling of promoter
regions [3,4]. Second, CaMKIIδ has been shown to
induce the expression of anti-apoptotic genes such as
BCL-2 through activating GATA4 [5]. Moreover, these
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two CaMKIIδ-activated factors, MEF2 and GATA4, can
synergistically enhance the expression of calcineurin
(PP2B), thereby inducing cardiac hypertrophy by trig-
gering calcineurin–NFAT signalling [6]. Intriguingly,
the positive transcription elongation factor P-TEFb
and its recruiting partner Brd4 are essential for car-
diac hypertrophy [7]. However, in an unstressed state,
P-TEFb is sequestrated into an inactive 7SK snRNP
complex and Brd4 is locked on chromatin. Our pre-
vious studies demonstrated that calcineurin together
with PP1α plays a critical role in activating P-TEFb
by liberating it from the inactive 7SK snRNP complex
[8], whereas PP1α together with class I HDACs plays
an essential role in releasing Brd4 from chromatin
[9]. Interestingly, to release chromatin-bound Brd4,
PP1α is used to dephosphorylate H3S10ph – the oppo-
site action of CaMKIIδ – and this dephosphorylation
leads to the deacetylation of nucleosomal histone
H4 at H4K5ac/K8ac by HDACs, thereby releasing
chromatin-bound Brd4. The released Brd4 subse-
quently binds to and recruits P-TEFb onto promoters to
enhance the expression of inducible genes [9].
As mentioned above, although many studies have
revealed the functional mechanisms of CaMKIIδ in car-
diac hypertrophy, a compensatory process for cardiomy-
ocyte survival, it remains unclear how CaMKIIδ controls
heart failure, an apparently opposite process involving
massive cardiomyocyte death. Nevertheless, the connec-
tion between CaMKIIδ-mediated phosphorylation of
H3S10 and the transcriptional reprogramming in both
pathological processes addressed by Awad et al has
opened a door for glancing at the progression from car-
diac hypertrophy to heart failure stage. Combined with
the conclusions of other research fields, it can be hypoth-
esized that at the very early stages of cardiac hypertro-
phy, the first genes subjected to transcription should be
the immediate-early genes, such as FOS, MYC, GATA4,
NFAT , NFKB, and MEF2. As transcription initiation
at the promoter regions of these genes has already
occurred, yet RNA polymerase II (RNAPII) is stalled at
the promoter-proximal regions in the unstressed state,
these genes are ready for rapid transcription elongation
by the recruitment of Brd4/P-TEFb in response to
stress [10]. Meanwhile, hypertrophic signals trigger
the liberation of P-TEFb from inactive 7SK snRNP
through calcineurin and PP1α signalling pathways [8],
and induce the release of chromatin-bound Brd4 via the
dephosphorylation of H3S10ph and the deacetylation
of H4K5ac/K8ac by activated PP1α and class I HDAC
pathways [9]. Released Brd4 subsequently binds to
P-TEFb and loads it onto paused RNAPII to stimulate
transcription elongation of the immediate-early genes.
Under the continuing stimulation of pathological
stress, the newly synthesized transcription factors
encoded by the immediate-early genes trigger transcrip-
tion of fetal cardiac genes such as ANP and β-MHC.
At this stage, increased CaMKIIδ kinase activity will
mediate the phosphorylation of H3S10 at the promoter
regions of fetal cardiac genes, inducing chromatin
remodelling to facilitate the recruitment of specific
transcription factors and assembly of the transcrip-
tion initiation complex. Of note, during this stage, the
kinase activity of CaMKIIδ in cardiomyocytes should
be limited and CaMKIIδ-mediated H3S10 phospho-
rylation restricted to promoter regions of fetal cardiac
genes, whereas the majority of nucleosomal H3S10ph
is dispersed and available for dephosphorylation by
PP1α, thereby aiding the release of chromatin-bound
Brd4 and the recruitment of P-TEFb to enhance tran-
scription elongation of fetal cardiac genes. Thus, by
the cooperation of specific transcription factors and the
transcription elongation factor Brd4/P-TEFb, a large
number of hypertrophic genes are expressed, causing
the heart to undergo substantial pathological changes.
To survive these pathological challenges, GATA4 also
mediates the expression of anti-apoptotic genes in a
Brd4-dependent manner [11]. Thus, at this hypertrophy
stage, the kinase activity of CaMKIIδ towards phospho-
rylating H3S10 and the phosphatase activity of PP1α
for dephosphorylating H3S10ph should be maintained
in an equilibrium state to enable cardiomyocytes to
survive the environmental challenges.
However, according to the observation of Awad et al,
both CaMKIIδ and H3S10ph were elevated during the
progression of cardiac hypertrophy and reached their
highest levels at the stage of heart failure. It is con-
ceivable that with the increase of CaMKIIδ, its kinase
activity would finally overwhelm the phosphatase activ-
ity of PP1α. In such a case, the H3S10-phosphorylated
nucleosomes would spill over the promoter regions and
spread to the gene body, even along the whole genome
[10]. Moreover, excessive CaMKIIδ kinase activity
would cause the export of class I HDACs together
with HDAC4 out of the nucleus, thereby indirectly
inducing global acetylation of nucleosomal H4K5/K8
[4,12]. As a result, Brd4 would be locked onto chro-
matin by acetylated H4K5/K8. Since PP1α-mediated
H3S10ph dephosphorylation is a prerequisite for the
deacetylation of H4K5ac/K8ac, the reduction of PP1α
activity would impair the release of chromatin-bound
Brd4 and the subsequent recruitment of P-TEFb for
a stress response [9]. When Brd4 becomes totally
unavailable, the Brd4-mediated stress response, such as
the expression of anti-apoptotic genes, would be com-
pletely stopped, thereby leading to the massive death of
cardiomyocytes. Thus, these events apparently switch
CaMKIIδ’s original role in compensatory responses to
pathological stress, to the inducer of cardiomyocyte
death.
Taken together, the underlying functions of CaMKIIδ
in different pathological stages are more complicated
than has been currently addressed. Therefore, it should
be recognized that any therapeutic strategy for cardiac
hypertrophy by administering a specific inhibitor may
raise the potential risk. In line with this notion, the
administration of CaMKII inhibitors at different patho-
logical stages has different, even opposite, effects [13].
Moreover, Brd4 is essential for cardiac hypertrophy and
inhibiting Brd4 with the specific inhibitor JQ-1 was able
to alleviate cardiac hypertrophy [7]. However, at the later
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stages of pathological hypertrophy, Brd4 might also be
essential for the survival of cardiomyocytes. If JQ-1 is
administered at this stage, it might cause the massive
death of cardiomyocytes and heart failure, rather than
alleviating hypertrophy, thereby raising potential risks
to heart patients. Therefore, broader and more detailed
molecular studies are required for deeper insights into
the processes involved in the development of cardiac
hypertrophy towards heart failure.
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